We put extraordinary talent in the room from day one — advisors hold equity alongside our management team, not a paid fee, so the people who've done this before are as invested in the outcome as you are.
That talent shares a common thread: ViroPharma and its alumni network, one of the most productive drug-development lineages in the industry. We've done this before — built companies from a handful of people to commercial launch, raised the capital to get there, and generated exits that returned real value to patients and investors alike.
That same team is ready to get your asset off the shelf and to patients, where it belongs. Talent like this is typically out of reach for an early-stage company. Our model changes that.
Our thesis is simple. There is no shortage of promising science sitting inside universities, hospitals, and biotechs — many of which never get the operational runway to reach a patient. We exist to find those assets, back them with battle-tested operators, and move them forward without wasting a dollar of capital along the way.
